- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- PB1046 Subcutaneous Injection
- Drug
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 2
- States / cities
- Columbus, Ohio • Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–13
of 13
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Heart Failure
- Interventions
- PB1046 Injection, Placebo Injection
- Drug
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 5
- States / cities
- Anniston, Alabama • Peoria, Arizona • Daytona Beach, Florida + 2 more
- Conditions
- Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
- Interventions
- Pemziviptadil (PB1046), Low Dose (10 mg) Control
- Drug
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- PE0139 Injection, Placebo
- Drug
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 3
- States / cities
- Anniston, Alabama • Hialeah, Florida • Renton, Washington
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl), Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)
- Drug
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Walnut Creek, California • Saint Paul, Minnesota • Renton, Washington
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- PB1023 Injection
- Drug
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Saint Paul, Minnesota • Knoxville, Tennessee
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Pemziviptadil (PB1046) Injection
- Drug
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 16
- States / cities
- La Jolla, California • Sacramento, California • Miami, Florida + 10 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- PE0139 Injection, Placebo Injection
- Drug
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 6
- States / cities
- Anniston, Alabama • Huntington Park, California • Bradenton, Florida + 3 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- 50 mg PB1023, 70 mg PB1023, 100 mg PB1023, Placebo (0.9% Sodium Chloride), Victoza®, Diet and Exercise, Metformin, Sulfonylurea, Metformin and Sulfonylurea
- Drug · Other
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 593 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 93
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more
- Conditions
- Essential Hypertension
- Interventions
- Placebo Single IV (Intravenous) Infusion, Experimental: Single IV Infusion Vasomera (PB1046)
- Drug
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Knoxville, Tennessee
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Single Dose PB1023
- Drug
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Pemziviptadil (PB1046)
- Drug
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 26
- States / cities
- Mobile, Alabama • Tucson, Arizona • La Jolla, California + 19 more
- Conditions
- Essential Hypertension
- Interventions
- Vasomera (PB1046), 0.9% Sodium Chloride
- Drug
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 5
- States / cities
- Anniston, Alabama • Walnut Creek, California • Saint Paul, Minnesota + 2 more